Gilead Sciences Inc
Symbol: GILD (NASDAQ)
111.20
▲ (0.18%) 0.195
Company Description:
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Key Stats
- Today's Open: $111.333
- Today's High: $111.34
- Today's Low: $110.85
- Today's Volume: 1.70K
- Yesterday Close: $111
- Yesterday High: $114.86
- Yesterday Low: $110.92
- Yesterday Volume: 10.30M
- Last Min Volume: 11
- Last Min High: $111.233
- Last Min Low: $111.195
- Last Min VWAP: $111.233
Company Profile
- Name: Gilead Sciences Inc
- Website: https://www.gilead.com
- Listed Date: 1992-01-22
- Location: FOSTER CITY, CA
- Market Status: Active
- CIK Number: 0000882095
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $137.73B
- Round Lot: 100
- Outstanding Shares: 1.24B
- Asset Type: CS
RECENT FILINGS FOR GILD
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-30 | 4 | View |
| 2025-09-29 | 144 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 3 | View |
| 2025-09-16 | 4 | View |
| 2025-09-16 | 4 | View |
| 2025-09-15 | 144 | View |
| 2025-09-15 | 144 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | N-PX | View |
| 2025-08-28 | 144 | View |
| 2025-08-18 | 4 | View |
| 2025-08-18 | 4 | View |
| 2025-08-15 | 144 | View |
| 2025-08-15 | 144 | View |
Latest News on GILD